Enalapril LPH

Quick links

Choose a section

Quick links to important sections

Advertisements

Enalapril LPH

Advertisements

Overview of Enalapril LPH

What is Enalapril LPH?

Enalapril LPH is a pharmaceutical formulation containing the active substance enalapril maleate. It belongs to a group of medications known as angiotensin-converting enzyme (ACE) inhibitors. This medication is primarily utilized in the management of cardiovascular conditions, specifically focusing on the regulation of blood pressure and the support of cardiac function.

Mechanism of Action

The active component, enalapril, is a prodrug that, after oral administration, is converted by the liver into its active metabolite, enalaprilat. This metabolite works by inhibiting the ACE enzyme, which is responsible for converting angiotensin I into angiotensin II. Angiotensin II is a potent substance in the body that causes blood vessels to narrow (vasoconstriction) and stimulates the release of hormones that increase blood volume. By blocking this process, Enalapril LPH facilitates the relaxation and widening of blood vessels, which helps to lower blood pressure and reduces the workload on the heart.

Therapeutic Indications

Enalapril LPH is indicated for several conditions related to the heart and circulatory system:

  • Hypertension: It is used to treat high blood pressure, helping to maintain it within a more stable range.
  • Heart Failure: It is used to manage symptomatic heart failure, a condition where the heart is unable to pump blood as efficiently as it should. In this context, the medication helps improve heart function and manage clinical symptoms.
  • Prevention of Symptomatic Heart Failure: It may be used in patients who do not yet show symptoms of heart failure but have a weakened left ventricle (asymptomatic left ventricular dysfunction), helping to delay or prevent the progression to symptomatic heart failure.
Advertisements

What side effects are possible with Enalapril LPH?

Possible Side Effects and Safety Information

The safety profile of Enalapril Maleate is established by regulatory documents that classify adverse reactions based on their frequency and the physiological system affected. These classifications are defined by major government health authorities, such as the FDA and the EMA.


Official Adverse Reaction Scope

Adverse reactions are formally grouped into categories reflecting incidence. Very Common effects (occurring in 1 or more in 10 patients) include cough and blurred vision. Common effects (occurring in 1 or more in 100 patients) often involve the nervous and cardiovascular systems, such as headache, dizziness, fatigue, and hypotension.

Less frequent, or Rare, reports include serious systemic events affecting the blood and liver, such as agranulocytosis and hepatic failure.


Serious Adverse Reactions and Safety Constraints

The most critical safety risk documented is Angioedema, a sudden swelling of the face, tongue, and larynx, which is potentially life-threatening. The official label also notes the risk of Symptomatic Hypotension, particularly when therapy is initiated or the dose is increased.

Specific restrictions on use are mandated by regulators. The medicine is contraindicated in individuals with a history of Angioedema related to prior ACE inhibitor use. Furthermore, due to the severe risk of fetal injury and death, Enalapril is strictly contraindicated during the second and third trimesters of pregnancy. Caution and monitoring are required for patients with renal impairment, as the risk of renal dysfunction is officially documented.

Advertisements

Overdose and Emergency Response

The official regulatory profile for an overdose of Enalapril Maleate (Enalapril LPH) is defined by the risk of acute cardiovascular and systemic collapse. The principal documented clinical manifestation is profound hypotension, or an excessive drop in blood pressure. This effect may cause severe dizziness, lightheadedness, or fainting.

Documented Severe Outcomes

A life-threatening overdose can escalate to more severe outcomes, including circulatory shock, stupor, and convulsions. Officially documented physiological complications include elevated potassium levels (hyperkalemia) and acute renal failure secondary to the severe hypotension. The severity of overdose is noted to be increased in patients with pre-existing severe heart failure or underlying renal disease.

Mandated Emergency Actions

Regulators mandate that individuals seek immediate medical attention for any suspected overdose or the onset of these severe symptoms. Treatment is defined as strictly symptomatic and supportive. There is no specific antidote known for ACE-inhibitor overdose. Described procedural steps for management include placing the patient in the supine position and administering intravenous fluids, such as normal saline, to counteract the low blood pressure. The official labeling states that the active metabolite, Enalaprilat, is dialyzable (removable by hemodialysis). Close observation and continuous hospital monitoring are required for any patient who is symptomatic or hypotensive following ingestion.

Advertisements

Therapeutic Uses of Enalapril LPH

What Enalapril LPH Treats: Main Uses and Benefits

Enalapril belongs to the category of medications known as angiotensin-converting enzyme (ACE) inhibitors. It is commonly used to help with conditions marked by increased physiological stress and is considered relevant in contexts involving heightened systemic burden.

Enalapril is indicated for the treatment of high blood pressure and heart failure. It is applied in addressing major conditions presenting with systemic or localized discomfort, including Hypertension (High Blood Pressure), symptomatic Heart Failure, and certain cases of Asymptomatic Left Ventricular Dysfunction.

In clinical scenarios, Enalapril supports patients during difficult episodes by easing distress and managing symptoms related to systemic imbalance and heightened physiological activity. It provides support that helps ease the overall symptom burden in conditions characterized by periods of heightened symptoms. It may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Is commonly used to help with symptoms related to heightened physiological activity

Overall, Enalapril contributes to easing the overall symptom load and supports general well-being during these symptomatic phases by providing supportive relief relevant in contexts involving heightened systemic burden.

Advertisements

Eligibility and Restrictions for Use

Enalapril LPH is officially approved for use in adults for managing hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction. Use is also established for children older than one month of age for hypertension.

However, regulatory documents define strict exclusions. The medicine is contraindicated in patients with a known hypersensitivity to enalapril or any other Angiotensin-Converting Enzyme (ACE) inhibitor. Absolute non-eligibility applies to anyone with a history of angioedema, including hereditary, idiopathic, or previous ACE inhibitor-related swelling.

Enalapril LPH is contraindicated during the second and third trimesters of pregnancy and must be discontinued immediately if pregnancy is detected. Use is not recommended for infants one month of age or younger, nor for pediatric patients with a severely impaired Glomerular Filtration Rate (GFR < 30 mL/min/1.73 m^2)

Furthermore, concomitant use with neprilysin inhibitors is contraindicated. Use with aliskiren is also prohibited in patients with diabetes or moderate-to-severe renal impairment. Patients with underlying renal or hepatic impairment and those who are volume-depleted require additional caution.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Classification Interacting Entity Official Interaction Description
Contraindicated Sacubitril/Valsartan (ARNI) Use is prohibited; must adhere to a 36-hour minimum time separation when switching between these medicines due to heightened angioedema risk.
Contraindicated Aliskiren Prohibited in patients with diabetes mellitus or existing renal impairment (GFR le 60 mL/min/1.73 m^2) due to increased risks of hypotension and hyperkalemia.
Pharmacodynamic Potassium-Sparing Diuretics (e.g., Amiloride, Spironolactone) Co-administration elevates the documented risk of Hyperkalemia (high serum potassium levels).
Pharmacodynamic NSAIDs (including COX-2 Inhibitors) May cause deterioration of renal function, including acute renal failure, especially in the elderly or volume-depleted patients.
Exposure Modifying Lithium Reduced renal clearance is documented, resulting in an officially described increase in serum Lithium levels and risk of toxicity.
Procedural Risk High-Flux Membranes Certain membranes (e.g., AN69) used in dialysis or LDL-apheresis are restricted due to the risk of anaphylactoid reactions.

The official regulatory profile is structured around two major prohibitions: mandatory timing separation with Sacubitril/Valsartan and a strict contraindication for dual RAS blockade with Aliskiren under specific conditions. Further documented interactions primarily involve pharmacodynamic effects, specifically increased risks of hyperkalemia with potassium-elevating agents and a risk of renal dysfunction with NSAIDs, all as defined in governmental labeling.

Advertisements

Mechanism of Action

Enalapril is a prodrug that undergoes rapid and complete hydrolysis in vivo, primarily in the liver, catalyzed by esterases, to yield its active metabolite, enalaprilat. Enalaprilat functions as a highly specific, competitive inhibitor of the angiotensin-converting enzyme (ACE).

ACE is a metalloprotease membrane-bound and soluble enzyme responsible for the cleavage of the decapeptide angiotensin I to the potent octapeptide angiotensin II. By inhibiting ACE, enalaprilat reduces the systemic generation of angiotensin II. The decreased concentration of angiotensin II subsequently diminishes its interaction with the angiotensin II type 1 (AT1) receptors located on vascular smooth muscle and in the adrenal cortex.

Intracellular consequences of reduced AT1 receptor activation include decreased vasoconstriction and diminished secretion of aldosterone. Aldosterone normally promotes sodium and water reabsorption in the distal tubules of the kidney. The systemic-level physiological consequences include vasodilation in both arterioles and veins and an increase in natriuresis and diuresis, leading to a net reduction in peripheral vascular resistance and circulating fluid volume.

Advertisements

Dosage and Administration Information

How to Use Enalapril LPH

Administration of Enalapril LPH involves specific routes, dosing regimens, and frequencies. The designated route for this medicine is oral, and it is available in tablet strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg. The tablets are intended to be swallowed whole with water and may be taken with or without food, as absorption is not affected by meals.

The required dosing frequency is typically once daily for uncomplicated hypertension or twice daily (divided doses) for the initiation and maintenance of symptomatic heart failure therapy.

Official Dosing Regimens (Adults)

Indication Initial Dose Maximum Daily Dose
Hypertension 5 mg once daily 40 mg daily
Heart Failure 2.5 mg twice daily 40 mg daily

For patients initiating heart failure treatment, the starting dose of 2.5 mg twice daily is gradually increased (titrated) over a period of two to four weeks under medical supervision. This gradual increase is a standard procedural step. Treatment for chronic conditions such as hypertension and heart failure is typically a long-term regimen.

Specific adjustments are utilized for certain populations. For instance, the initial dose is reduced to 2.5 mg once daily for adult patients with moderate to severe renal impairment (Creatinine Clearance leq 30 mL/min) and for patients undergoing dialysis. If a dose is missed, the standard procedure is to omit the missed dose and take the next dose at the regularly scheduled time without taking a double dose.

Advertisements

Recent Clinical Evidence

Enalapril LPH: Recent Clinical Evidence

This section summarizes findings from clinical research and trials involving enalapril, the active component of Enalapril LPH, with a focus on its primary approved uses.


Evaluation in Hypertension

Randomized controlled trials (RCTs) have consistently evaluated the use of enalapril in the management of essential hypertension. Studies examining long-term outcomes have focused on sustained changes in blood pressure, including both systolic and diastolic measurements. Researchers explore the extent to which enalapril administration is associated with the reduction of high blood pressure when compared to placebo or other antihypertensive agents.

Findings from meta-analyses have examined data pooled from multiple RCTs, exploring the association between enalapril use and a potential decrease in major cardiovascular events over several years of observation.


Role in Heart Failure

Enalapril has been extensively studied for its potential role in the treatment of symptomatic heart failure. These trials included patients with reduced left ventricular ejection fraction. Research examined whether the administration of enalapril was associated with effects on measures such as exercise capacity, New York Heart Association (NYHA) functional class, and overall hospitalization rates.

Exploratory analyses sometimes investigate secondary endpoints, such as the association between the drug's use and changes in quality of life indicators reported by study participants.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Enalapril LPH (FAQ)

Q: How does Enalapril LPH work to reduce the workload on the heart?

Enalapril, after being converted into its active form, enalaprilat, works by inhibiting the Angiotensin-Converting Enzyme (ACE). This action blocks the creation of a hormone that typically causes blood vessels to narrow. By stopping this narrowing, the medicine allows blood vessels to widen (vasodilation), which lowers the overall resistance to blood flow and ultimately helps to ease the workload on the heart.


Q: Is Enalapril LPH a beta-blocker or an ACE inhibitor?

According to official product information, Enalapril LPH contains Enalapril Maleate, which is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor. This class of medicine targets a specific enzyme system in the body.


Q: Is it normal to feel dizzy or lightheaded when starting Enalapril LPH?

Official safety data lists dizziness as a common adverse reaction. Feeling lightheaded, often caused by hypotension (low blood pressure), is also a documented common effect. The official label notes that this can be a particular concern when initiating treatment or following a dose increase.


Q: Can older adults safely take Enalapril LPH?

Official labeling does not prohibit the use of Enalapril in older adults. However, the dose may require adjustment for patients with pre-existing renal impairment (kidney issues), a condition that is more common in older populations. Dosage requires careful individualization based on a patient's specific health status.


Q: What are the signs of a serious allergic reaction to Enalapril LPH?

A critical serious risk documented is Angioedema, a potentially severe form of swelling. Regulatory documents state that this involves sudden swelling of the face, tongue, lips, throat, and/or voice box (larynx). This severe reaction may occur at any point during treatment.


Q: What are some less common but serious side effects of Enalapril LPH to watch out for?

While rare, official safety reports document serious effects that can affect the blood and liver. These include systemic events such as agranulocytosis (a decrease in certain white blood cells) and hepatic failure (severe liver problems). These are much less frequent than common side effects like cough or headache.


Q: Is Enalapril LPH prescribed for anything other than high blood pressure and heart failure?

Yes, regulatory documents indicate that Enalapril is also approved for the treatment of asymptomatic left ventricular dysfunction. This is a condition where the heart's main pumping chamber is weakened but has not yet caused symptoms of overt heart failure.


Q: Are there studies supporting the use of Enalapril LPH during pregnancy or breastfeeding (as a general curiosity, without asking for individual advice)?

Official information indicates that use during the second and third trimesters of pregnancy is strictly contraindicated due to the serious risk of harm to the fetus. Furthermore, regulatory guidelines advise against breastfeeding while the medicine is being taken.


Q: What foods or supplements should not be taken with Enalapril LPH?

Official safety information notes that the absorption of the medicine is not generally affected by food. However, official guidance suggests avoiding supplements or salt substitutes that contain potassium. Combining the medicine with high-potassium agents can increase the risk of developing dangerously high potassium levels in the blood (Hyperkalemia).


Q: How is Enalapril LPH eliminated from the body?

Once the medicine is converted into its active form, Enalaprilat, it is primarily eliminated through the kidneys (renal excretion). Official pharmacokinetic data shows that the majority of the dose is recovered through the urine and feces in the form of the active drug or the original compound.


Q: Are there any known issues with combining Enalapril LPH with certain cold medicines?

According to the official product summary, Enalapril LPH may interact with medicines used to treat low blood pressure, asthma, or allergies, such as ephedrine, noradrenaline, or adrenaline. These types of compounds are often ingredients found in certain non-prescription cold and flu preparations when a patient takes this medicine.


Q: When is the effect of Enalapril LPH at its peak after taking a dose?

Official pharmacokinetic studies indicate that the active metabolite, Enalaprilat, reaches its peak concentration in the bloodstream approximately three to four hours after the oral tablet is administered. This timeframe represents the peak concentration of the active medication in the blood.


Q: Can Enalapril LPH cause fatigue or tiredness?

Fatigue is one of the common adverse reactions reported in clinical trials involving patients treated for high blood pressure. This adverse effect is frequently noted in official safety data.


Q: Why do some people take Enalapril LPH twice a day?

The medicine is sometimes administered twice daily if the blood pressure-lowering effect is found to lessen by the end of the 24-hour period. A twice-daily dose regimen is also typically used when starting treatment for symptomatic heart failure.


Q: Is it possible for Enalapril LPH to make my cough worse over time?

The most common adverse reaction is a persistent, nonproductive cough, which is characteristic of ACE inhibitors. The official label notes the frequency of this effect. The cough generally resolves after the medicine is discontinued.


Q: Is it safe to drive or operate machinery while taking Enalapril LPH?

Official regulatory warnings suggest that the ability to drive or operate machinery may be impaired by certain common side effects. Specifically, reactions like dizziness or fatigue can be an issue, especially when treatment begins or when the dose is increased.


Q: Can Enalapril LPH cause changes in my sense of taste?

Yes, taste alteration or a change in your sense of taste is listed in official documents as one of the less frequent adverse reactions reported for this medication.


Q: Does long-term use of Enalapril LPH have any specific risks?

As the medicine is often used as a long-term regimen for chronic conditions, official guidance emphasizes the importance of continued monitoring for potential long-term risks. This includes checking for potential issues such as the deterioration of kidney function (renal dysfunction) and the development of high blood potassium levels (hyperkalemia).


Q: Can Enalapril LPH cause stomach upset or nausea?

Official safety data lists nausea as a common adverse reaction affecting the gastrointestinal system in patients taking this medicine.

Advertisements

How should Enalapril LPH be stored and disposed of?

How to Store and Dispose of Enalapril LPH?

The storage and disposal of Enalapril LPH (enalapril maleate) tablets must strictly follow regulatory requirements to maintain stability and ensure safe handling.

Storage Conditions

Enalapril maleate tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be stored away from excess heat and moisture and must remain in the original container, kept tightly closed.

For safety, the medication must be stored out of the reach of children.

Disposal Requirements

Unused or expired Enalapril LPH must be disposed of according to local regulations. Patients are advised to consult a pharmacist about community drug take-back programs. The product should not be flushed down the toilet unless explicitly instructed to do so on the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Enalapril LPH found in:

A-Z Index: